Overview
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2023-08-31
2023-08-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bristol-Myers SquibbCollaborator:
AbbVieTreatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Elotuzumab
Lenalidomide
Nivolumab
Pomalidomide
Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, pleasevisit www.BMSStudyConnect.com
Inclusion Criteria:
- Participated in a previous elotuzumab protocol (including, but not limited to
HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be
deriving benefit from elotuzumab and/or other study drugs as defined by the previous
protocol
- Receiving elotuzumab and/or other study drugs at the time of signature of informed
consent
- Males and Females, ages 18 and older
Exclusion Criteria:
- All participants previously discontinued from an elotuzumab study for any reason
- Participants not receiving clinical benefit from previous study therapy
- Participants who are not medically well enough to receive study therapy as determined
by the investigator
Other protocol defined inclusion/exclusion criteria could apply